DE60044259D1 - HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER - Google Patents

HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER

Info

Publication number
DE60044259D1
DE60044259D1 DE60044259T DE60044259T DE60044259D1 DE 60044259 D1 DE60044259 D1 DE 60044259D1 DE 60044259 T DE60044259 T DE 60044259T DE 60044259 T DE60044259 T DE 60044259T DE 60044259 D1 DE60044259 D1 DE 60044259D1
Authority
DE
Germany
Prior art keywords
receptors
hiv
human anti
igm antibodies
igm autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044259T
Other languages
German (de)
English (en)
Inventor
Peter I Lobo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60044259D1 publication Critical patent/DE60044259D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
DE60044259T 1999-11-15 2000-11-14 HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER Expired - Lifetime DE60044259D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43969099A 1999-11-15 1999-11-15
US09/684,813 US6610834B1 (en) 1998-11-18 2000-10-10 Human IgM antibodies to chemokine receptors
PCT/US2000/031051 WO2001035980A1 (en) 1999-11-14 2000-11-14 HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS

Publications (1)

Publication Number Publication Date
DE60044259D1 true DE60044259D1 (de) 2010-06-02

Family

ID=27032133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044259T Expired - Lifetime DE60044259D1 (de) 1999-11-15 2000-11-14 HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER

Country Status (8)

Country Link
US (1) US6610834B1 (https=)
EP (1) EP1231930B1 (https=)
JP (1) JP2003516940A (https=)
AT (1) ATE464909T1 (https=)
AU (1) AU1599601A (https=)
CA (1) CA2389851A1 (https=)
DE (1) DE60044259D1 (https=)
WO (1) WO2001035980A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118522A1 (en) * 1998-11-18 2008-05-22 Lobo Peter I Naturally occuring IgM antibodies that bind lymphocytes
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
CN1997893A (zh) * 2004-04-16 2007-07-11 健泰科生物技术公司 抗体测定法
EP1817054A1 (en) * 2004-12-01 2007-08-15 Peter I. Lobo Naturally occuring igm antibodies that bind lymphocytes
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP2009531283A (ja) 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2054086A1 (en) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG A conjugate of an antibody against ccr5 and an antifusogenic peptide
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2017140794A1 (en) * 2016-02-16 2017-08-24 Celltrend Gmbh Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
WO1997049424A1 (en) * 1996-06-25 1997-12-31 The Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JP2000229997A (ja) * 1999-02-10 2000-08-22 Nissui Pharm Co Ltd 環状ペプチド及びエイズワクチン

Also Published As

Publication number Publication date
WO2001035980A1 (en) 2001-05-25
US6610834B1 (en) 2003-08-26
CA2389851A1 (en) 2001-05-25
EP1231930B1 (en) 2010-04-21
EP1231930A1 (en) 2002-08-21
JP2003516940A (ja) 2003-05-20
ATE464909T1 (de) 2010-05-15
EP1231930A4 (en) 2005-07-27
AU1599601A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
Melenotte et al. Immune responses during COVID-19 infection
DE60044259D1 (de) HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER
Clerici et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41
Doria-Rose et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
Michaud et al. Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
Sandberg et al. SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
Kohler et al. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination
Johansson et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients
Hosie et al. A monoclonal antibody which blocks infection with feline immunodeficiency virus identifies a possible non-CD4 receptor
EA200300336A1 (ru) Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Melchers et al. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses
Klasse et al. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
Kulkarni et al. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of envelope and a region from Tat protein
Greczmiel et al. LCMV‐specific CD4 T cell dependent polyclonal B‐cell activation upon persistent viral infection is short lived and extrafollicular
Nelson et al. Simian-human immunodeficiency virus SHIV. CH505-infected infant and adult rhesus macaques exhibit similar env-specific antibody kinetics, despite distinct T-follicular helper and germinal center B cell landscapes
Hochleitner et al. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Brocca-Cofano et al. Pathogenic correlates of simian immunodeficiency virus-associated B cell dysfunction
Lizeng et al. Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals
Vieillard et al. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection
Tingstedt et al. The impact of concurrent HIV and type II diabetes on immune maturation, immune regulation and immune activation
Lozano Reina et al. Gag p27-specific B-and T-cell responses in Simian immunodeficiency virus SIVagm-infected African green monkeys
Lawoko et al. Increased immunoglobulin G, but not M, binding to endogenous retroviral antigens in HIV‐1 infected persons
Sattentau et al. New templates for HIV-1 antibody-based vaccine design

Legal Events

Date Code Title Description
8364 No opposition during term of opposition